
Aprea Therapeutics Reports Positive Interim Data for APR-1051 Trial
Aprea Therapeutics, Inc. announced updated interim results from its Phase 1 ACESOT-1051 trial of APR-1051, an investigational WEE1 inhibitor. The trial showed preliminary evidence of clinical activity, including one confirmed and one unconfirmed partial response in patients with PPP2R1A-mutated uterine cancers, and five patients with stable disease lasting over four months. The company also updated its corporate presentation, detailing the drug's safety profile, pharmacodynamic data demonstrating target engagement, and pharmacokinetic data supporting once-daily administration. Aprea plans to expand enrollment into focused cohorts for uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer.
Key Highlights
- Aprea Therapeutics announced updated interim results from its Phase 1 ACESOT-1051 trial of APR-1051.
- Two patients with PPP2R1A-mutated uterine cancers achieved RECIST 1.1 partial responses (one confirmed, one unconfirmed).
- Five patients achieved stable disease lasting more than four months.
- Pharmacodynamic data showed WEE1 target engagement across multiple dose levels (84% of evaluable patients).
- One dose-limiting toxicity (DLT) observed among 56 treated patients.
- Grade 3/4 neutropenia reported in 7% of patients; two patients (4%) experienced Grade 3 pneumonitis.
- Pharmacokinetics support once-daily administration with an approximately 18-hour median half-life.
- Aprea plans to enroll patients in focused cohorts for uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer.
Price Impact
More from APRE